Trials / Completed
CompletedNCT02797951
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC |
Timeline
- Start date
- 2016-07-13
- Primary completion
- 2021-01-21
- Completion
- 2021-01-21
- First posted
- 2016-06-14
- Last updated
- 2022-02-10
- Results posted
- 2022-02-10
Locations
40 sites across 12 countries: United States, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02797951. Inclusion in this directory is not an endorsement.